| Comparative financing analysis and political economy of noncommunicable diseases |
30 |
| Cost-effectiveness of pembrolizumab in combination with chemotherapy in the 1st line treatment of non-squamous NSCLC in the US |
24 |
| Medication adherence and discontinuation of long-acting injectable versus oral antipsychotics in patients with schizophrenia or bipolar disorder |
15 |
| Cost-effectiveness of axicabtagene ciloleucel for adult patients with relapsed or refractory large B-cell lymphoma in the United States |
14 |
| The value of self-medication: summary of existing evidence |
12 |
| The burden of osteoporosis in four Latin American countries: Brazil, Mexico, Colombia, and Argentina |
11 |
| The association between adherence to levothyroxine and economic and clinical outcomes in patients with hypothyroidism in the US |
10 |
| Cost-effectiveness of TYRX absorbable antibacterial envelope for prevention of cardiovascular implantable electronic device infection |
9 |
| Budget impact analysis of comprehensive genomic profiling in patients with advanced non-small cell lung cancer |
8 |
| Cost-effectiveness analysis of first-line pembrolizumab treatment for PD-L1 positive, non-small cell lung cancer in China |
8 |
| Cost-utility analysis of life-long prophylaxis with recombinant factor VIIIFc vs recombinant factor VIII for the management of severe hemophilia A in Sweden |
8 |
| Cost-effectiveness of mechanical thrombectomy for acute ischemic stroke: an Australian payer perspective |
8 |
| Patient preferences and health state utilities associated with dulaglutide and semaglutide injection devices among patients with type 2 diabetes in Italy |
7 |
| A systematic review of pharmacoeconomic guidelines |
7 |
| Cost-effectiveness analysis of standalone trabecular micro-bypass stents in patients with mild-to-moderate open-angle glaucoma in Canada |
7 |
| Influencing factors of disability among the elderly in China, 2003-2016: application of Bayesian quantile regression |
6 |
| Cost-effectiveness of cladribine tablets, alemtuzumab, and natalizumab in the treatment of relapsing-remitting multiple sclerosis with high disease activity in England |
6 |
| Prevalence and economic burden of comorbid anxiety and depression among patients with moderate-to-severe psoriasis |
6 |
| Estimated annual and lifetime labor productivity in the United States, 2016: implications for economic evaluations |
6 |
| Cost-effectiveness analyses using real-world data: an overview of the literature |
6 |
| Cost-effectiveness analysis of dapagliflozin treatment versus metformin treatment in Chinese population with type 2 diabetes |
6 |
| Cost-effectiveness of second-line atezolizumab in Canada for advanced non-small cell lung cancer (NSCLC) |
6 |
| Cost-effectiveness of pembrolizumab for the adjuvant treatment of resected high-risk stage III melanoma in the United States |
6 |
| Comparison of costs and outcomes of dapagliflozin with other glucose-lowering therapy classes added to metformin using a short-term cost-effectiveness model in the US setting |
6 |
| Cost estimate of platelet transfusion in the United States for patients with chronic liver disease and associated thrombocytopenia undergoing elective procedures |
6 |
| Treatment patterns, healthcare resource utilization, and costs in patients with acute myeloid leukemia in commercially insured and Medicare populations |
6 |
| Pilot study assessing the direct medical cost of treating patients with cancer in Kenya; findings and implications for the future |
5 |
| Healthcare resource utilization and costs among psoriasis patients treated with biologics, overall and by disease severity |
5 |
| Healthcare resource utilization and costs in patients with newly diagnosed acute myeloid leukemia |
5 |
| Treatment patterns and predictors of costs among patients with migraine: evidence from the United States medical expenditure panel survey |
5 |
| A discrete-choice experiment to assess treatment modality preferences of patients with depression |
5 |
| Real-world treatment patterns and healthcare costs among biologic-naive patients initiating apremilast or biologics for the treatment of psoriasis |
5 |
| Cost-effectiveness of grass pollen subcutaneous immunotherapy (SCIT) compared to sublingual immunotherapy (SLIT) and symptomatic treatment in Austria, Spain, and Switzerland |
5 |
| Economic and quality of life burden of anemia on patients with CKD on dialysis: a systematic review |
4 |
| Cost-effectiveness of brentuximab vedotin plus chemotherapy as frontline treatment of stage III or IV classical Hodgkin lymphoma |
4 |
| The economic burden of psoriasis with high comorbidity among privately insured patients in the United States |
4 |
| Does the critical illness insurance reduce patients' financial burden and benefit the poor more: a comprehensive evaluation in rural area of China |
4 |
| Postprandial glucose and healthcare resource use: a cross-sectional survey of adults with diabetes treated with basal-bolus insulin |
4 |
| Societal burden of cluster headache in the United States: a descriptive economic analysis |
4 |
| Identifying cost-effective screening algorithms for active hepatitis C virus infections in a high prevalence setting |
4 |
| Converting EORTC QLQ-C30 scores to utility scores in the brigatinib ALTA study |
4 |
| Systematic review and analysis of efficacy of recombinant factor IX products for prophylactic treatment of hemophilia B in comparison with rIX-FP |
4 |
| Cohort versus patient level simulation for the economic evaluation of single versus combination immuno-oncology therapies in metastatic melanoma |
4 |
| Economic impact model of delayed inhibitor development in patients with hemophilia a receiving emicizumab for the prevention of bleeding events |
4 |
| The economic burden of depression among adults with rheumatoid arthritis in the United States |
4 |
| Tumor treating fields and maintenance temozolomide for newly-diagnosed glioblastoma: a cost-effectiveness study |
4 |
| Cost-effectiveness of osimertinib in the UK for advanced EGFR-T790M non-small cell lung cancer |
4 |
| Cost-effectiveness analysis of secukinumab for the treatment of active psoriatic arthritis: a Canadian perspective |
4 |
| Healthcare costs in patients with advanced non-small cell lung cancer and disease progression during targeted therapy: a real-world observational study |
4 |
| Tofacitinib in the treatment of moderate-to-severe rheumatoid arthritis: a cost-effectiveness analysis compared with adalimumab in Taiwan |
4 |
